87 related articles for article (PubMed ID: 24702959)
1. Doxorubicin-loaded silicon nanowires for the treatment of drug-resistant cancer cells.
Peng F; Su Y; Ji X; Zhong Y; Wei X; He Y
Biomaterials; 2014 Jun; 35(19):5188-95. PubMed ID: 24702959
[TBL] [Abstract][Full Text] [Related]
2. Enhanced doxorubicin delivery and cytotoxicity in multidrug resistant cancer cells using multifunctional magnetic nanoparticles.
Pilapong C; Keereeta Y; Munkhetkorn S; Thongtem S; Thongtem T
Colloids Surf B Biointerfaces; 2014 Jan; 113():249-53. PubMed ID: 24103503
[TBL] [Abstract][Full Text] [Related]
3. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
Shen J; He Q; Gao Y; Shi J; Li Y
Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization of doxorubicin in multidrug-resistant cells by unimolecular micelles via increased cellular accumulation and apoptosis.
Wang M; Han M; Li Y; Jin Y; Gao JQ
J Pharm Pharmacol; 2016 Mar; 68(3):333-41. PubMed ID: 26893058
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells.
Miao J; Du YZ; Yuan H; Zhang XG; Hu FQ
Colloids Surf B Biointerfaces; 2013 Oct; 110():74-80. PubMed ID: 23711779
[TBL] [Abstract][Full Text] [Related]
7. Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells.
Wang YC; Wang F; Sun TM; Wang J
Bioconjug Chem; 2011 Oct; 22(10):1939-45. PubMed ID: 21866903
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin and chloroquine coencapsulated liposomes: preparation and improved cytotoxicity on human breast cancer cells.
Qiu L; Yao M; Gao M; Zhao Q
J Liposome Res; 2012 Sep; 22(3):245-53. PubMed ID: 22607110
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
Zeng X; Morgenstern R; Nyström AM
Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
[TBL] [Abstract][Full Text] [Related]
10. Electroactive polypyrrole nanowire arrays: synergistic effect of cancer treatment by on-demand drug release and photothermal therapy.
Lee H; Hong W; Jeon S; Choi Y; Cho Y
Langmuir; 2015 Apr; 31(14):4264-9. PubMed ID: 25815804
[TBL] [Abstract][Full Text] [Related]
11. Gold nanorod-cored biodegradable micelles as a robust and remotely controllable doxorubicin release system for potent inhibition of drug-sensitive and -resistant cancer cells.
Zhong Y; Wang C; Cheng L; Meng F; Zhong Z; Liu Z
Biomacromolecules; 2013 Jul; 14(7):2411-9. PubMed ID: 23701318
[TBL] [Abstract][Full Text] [Related]
12. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
[TBL] [Abstract][Full Text] [Related]
13. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z
Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799
[TBL] [Abstract][Full Text] [Related]
14. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
15. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
Ogretmen B; McCauley MD; Safa AR
Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
[TBL] [Abstract][Full Text] [Related]
18. Characterization and anti-tumor activity of chemical conjugation of doxorubicin in polymeric micelles (DOX-P) in vitro.
Zhao YZ; Sun CZ; Lu CT; Dai DD; Lv HF; Wu Y; Wan CW; Chen LJ; Lin M; Li XK
Cancer Lett; 2011 Dec; 311(2):187-94. PubMed ID: 21872982
[TBL] [Abstract][Full Text] [Related]
19. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells.
Zhang XG; Miao J; Dai YQ; Du YZ; Yuan H; Hu FQ
Int J Pharm; 2008 Sep; 361(1-2):239-44. PubMed ID: 18586075
[TBL] [Abstract][Full Text] [Related]
20. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
